• Luis García de Guadiana-Romualdo, María Dolores Albaladejo-Otón, Mario Berger, Enrique Jiménez-Santos, Roberto Jiménez-Sánchez, Patricia Esteban-Torrella, Sergio Rebollo-Acebes, Ana Hernando-Holgado, Alejandro Ortín-Freire, and Javier Trujillo-Santos.
• Clinical Chemistry Laboratory, Santa Lucía Hospital, Cartagena, Spain.
• Biomark Med. 2019 Dec 1; 13 (17): 1469-1480.

AbstractAim: To assess the prognostic value for 28-day mortality of PSP in critically ill patients with sepsis. Material & methods: 122 consecutive patients with sepsis were enrolled in this study. Blood samples were collected on admission and day 2. Results: On admission, the combination of PSP and lactate achieved an area under the receiver operating characteristic (AUC-ROC) of 0.796, similar to sequential organ failure assessment score alone (AUC-ROC: 0.826). On day 2, PSP was the biomarker with the highest performance (AUC-ROC: 0.844), although lower (p = 0.041) than sequential organ failure assessment score (AUC-ROC: 0.923). Conclusion: The combination of PSP and lactate and PSP alone, on day 2, have a good performance for prognosis of 28-day mortality and could help to identify patients who may benefit most from tailored intensive care unit management.

29 keywords...

hide…